Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 20/20 | 0.75 |
| ▸ | KDR | P35968 | 19/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 18/20 | 0.75 |
| ▸ | FGFR4 | P22455 | 18/20 | 0.75 |
| ▸ | FGFR2 | P21802 | 17/20 | 0.75 |
| ▸ | FLT3 | P36888 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16132959 | 0.91 | FGFR1 (0.75) | FGFR3KDRFGFR1FGFR4FGFR2 | |
| SCHEMBL14906768 | 0.89 | FGFR3 (0.75) | FGFR3KDRFGFR1FGFR4FGFR2 | |
| SCHEMBL18675926 | 0.87 | FGFR3 (0.75) | FGFR3KDRFGFR1FGFR4FGFR2 | |
| SCHEMBL18675934 | 0.87 | FGFR1 (0.77) | FGFR3KDRFGFR1FGFR4FGFR2 | |
| SCHEMBL24400202 | 0.86 | FGFR3 (0.76) | FGFR3KDRFGFR1FGFR4FGFR2 | |
| SCHEMBL2592848 | 0.86 | FGFR3 (1.00) | FGFR3KDRFGFR1FGFR4FGFR2 | |
| SCHEMBL14906807 | 0.86 | FGFR1 (0.60) | FGFR3KDRFGFR1FGFR4FGFR2 | |
| SCHEMBL19650226 | 0.86 | FGFR3 (0.57) | FGFR3KDRFGFR1FGFR4FGFR2 | |
| SCHEMBL16132950 | 0.86 | FGFR3 (0.60) | FGFR3KDRFGFR1FGFR4FGFR2 | |
| SCHEMBL14906705 | 0.85 | FGFR1 (0.69) | FGFR3KDRFGFR1FGFR4FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039759-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2018-08-07 | — | — | US | disclosed |
| US-10039759-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2018-08-07 | — | — | US | disclosed |
| EP-2776397-B1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2017-11-29 | — | — | EP | disclosed |
| US-9439896-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2016-09-13 | — | — | US | disclosed |
| US-9439896-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2016-09-13 | — | — | US | disclosed |
| US-20140296236-A1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140296236-A1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| WO-2013061074-A1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039759-B2 | Quinolines as FGFR kinase modulators | FGFR1, FGFR3, FGFR2 | FGFR3 2/4885KDR 74/4885FGFR1 1/4885 |
| US-20140296236-A1 | QUINOLINES AS FGFR KINASE MODULATORS | FGFR1, FGFR2, FGFR3 | FGFR3 3/4885KDR 65/4885FGFR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.